Additional file 1: of S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial

SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 124 kb

Additional file 1: of Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial

SPIRIT 2013 Checklist. (DOC 124 kb

Baseline characteristics of the study population.

<p>AA, aldosterone receptor antagonist; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta-blocker; BMI, body mass index; BNP, b-type natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary bypass graft surgery; CK-MB, creatine kinase-MB fraction; DBP, diastolic blood pressure; ECG, electrocardiography; HR, heart rate; IQR, interquartile range; LA AP, left atrium anterior-posterior; LBBB, left bundle branch block; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal-proBNP; NYHA, New York Heart Association; PAOD, peripheral artery obstructive disease; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; SBP, systolic blood pressure; SD, standard deviation</p

Drug adherence.

<p>ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor II blocker</p

Dataset for the study population.

<p>LVEF, left ventricular ejection fraction; f/u, follow-up.</p

Relationship between performance measures/guideline adherence at discharge and clinical outcomes.

<p>ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta-blocker; AA, aldosterone antagonist; CI, confidence interval; HR, hazard ratio; NYHA, New York Heart Association</p>*<p>Adjusted for age; history of heart failure, ischemic heart failure, diabetes mellitus, and peripheral vascular disease; diastolic blood pressure; blood urea nitrogen; serum creatinine, sodium, and potassium; hemoglobin levels; and NYHA functional classification.</p

Adjusted Cox-regression analysis for 1-year mortality at in subgroups according to guideline adherence: Forest plot.

<p>HTN, hypertension; DM, diabetes mellitus; HF, heart failure; LVEF, left ventricular ejection fraction; Cr, creatinine.</p

Unadjusted event-free curves for overall mortality and re-hospitalization in HF patients with good and poor guideline adherence at discharge.

<p>(A) overall mortality and (B) re-hospitalization. HF, heart failure; Good, good guideline adherence; Poor, poor guideline adherence; Line, good guideline adherence; dotted line, poor guideline adherence.</p